Liraglutide at a daily dose of 3 mg is the first GLP-1 RA registered for non-syndromic obesity treatment, with a mean weight change of 8% in individuals with obesity without diabetes (29) and 6% in individuals with obesity and diabetes (30). The gene discussed is GLP1R; the disease is obesity disorder.